Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults
The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.
You may also be interested in...
In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.
Adela raised $60m to advance its DNA methylation technology for early cancer detection and disease monitoring.